Logo

Nykode Reports the Completion of Patient Enrollment in P-II Trial of VB10.16 + Atezolizumab for the Treatment of Advanced Cervical Cancer

Share this

Nykode Reports the Completion of Patient Enrollment in P-II Trial of VB10.16 + Atezolizumab for the Treatment of Advanced Cervical Cancer

Shots:

  • The company has completed the patient enrollment in P-II study to evaluate Nykode’s  VB10.16 + Roche’s atezolizumab (checkpoint inhibitor) in 50 patients with advanced or recurrent, non-resectable HPV16-positive cervical cancer who failed or are not eligible for current SoC across 20 sites in 6 EU countries
  • The company is expected an interim efficacy and safety data from the first patients in H1’22 & is also planning to evaluate VB10.16 in other HPV-driven cancers, including head and neck cancer
  • VB10.16 is an off-the-shelf therapeutic HPV16 cancer vaccine that is designed to induce strong HPV16 specific T cell responses for the treatment of HPV16-positive cancers

to­ Ref: Globenewswire | Image: Linkedin

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions